Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22126589 | 1.00 | NAMPT (0.40) | NAMPTUSP30KDM4EGPR119SMN1; SMN2 | |
| SCHEMBL31200501 | 0.88 | NAMPT (0.40) | NAMPTUSP30KDM4ESMN1; SMN2MAPT | |
| SCHEMBL22126597 | 0.84 | USP30 (0.58) | USP30GPR119 | |
| SCHEMBL29545936 | 0.84 | USP30 (0.58) | USP30GPR119 | |
| SCHEMBL22126595 | 0.84 | USP30 (0.58) | USP30GPR119 | |
| SCHEMBL22126591 | 0.81 | NAMPT (0.41) | NAMPTUSP30 | |
| SCHEMBL31200834 | 0.81 | MAPT (0.41) | USP30GPR119SMN1; SMN2USP2MAPT | |
| SCHEMBL20031443 | 0.81 | NAMPT (0.41) | NAMPTUSP30 | |
| SCHEMBL31200522 | 0.81 | MAPT (0.41) | USP30GPR119SMN1; SMN2USP2MAPT | |
| SCHEMBL31200641 | 0.79 | NLRP3 (0.44) | NAMPTUSP30GPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519412-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-12-01 | — | — | EP | disclosed |
| US-11084821-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| US-20200199126-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-25 | — | — | US | disclosed |
| WO-2018060742-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199126-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP1, USP28 | NAMPT 3274/4885USP30 1/4885KDM4E 1215/4885 |
| US-11084821-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | USP30, USP39, USP28 | NAMPT 3287/4885USP30 1/4885KDM4E 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.